secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-09-04T10:01:59+00:00
Accession:  0001140361-26-035657
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Ionis' ZANVASTRO (zilganersen) for Alexander disease
-----------------------------------------------------------------

- ZANVASTRO is first and only disease-modifying treatment for AxD; 50 mg intrathecal quarterly.
- Pivotal study met primary endpoint: gait speed stabilization at Week 61 (LS mean diff 33.3%, p=0.041).
- FDA granted Rare Pediatric Disease Priority Review Voucher with approval.
- Recordati holds ex-U.S. rights; EU/Japan regulatory submissions expected in 2027.
- ZANVASTRO available in U.S. in coming weeks; Ionis' first independent neurology launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126035657/0001140361-26-035657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126035657/ef20081649_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-035657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer